NVS wins full FDA approval for Fabhalta in IgA nephropathy after phase III data shows slower kidney function decline, ...
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Zura Bio , Insmed and Harmony Biosciences Holdings . TipRanks Welcomes a New ETF ...
EVEREST MED (01952.HK) announced that, in relation to the exclusive licensing and collaboration agreement signed with Travere ...
Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.
Recently published Alport Syndrome Market Insights report includes a comprehensive understanding of current treatment practices, Alport syndrome emerging drugs, market share of individual therapies, ...
Travere Therapeutics Inc. company and executive profile by Barron's. View the latest TVTX company infomation and executive bios.
With two approved medicines to treat primary immunoglobulin A nephropathy (IgAN) and a third therapy in phase 3 testing, ...
With combination therapies and multiple treatment options available for patients, nephrology is in a “therapeutic revolution, ...
View Ligand Pharmaceuticals Incorporated LGND stock quote prices, financial information, real-time forecasts, and company news from CNN.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results